A Study of Eszopiclone Co-administered With Venlafaxine in Subjects With Major Depressive Disorder and Insomnia
A 31-Week, Efficacy, Safety and Tolerability Study of Eszopiclone 3 mg Co-administered With Venlafaxine in Subjects With Major Depressive Disorder (MDD) and Co-existing Insomnia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Salzburg, Austria
-
Wien, Austria, A-1010
-
Wien, Austria, A-1090
-
-
-
-
-
Split, Croatia, 21 000
-
Zagreb, Croatia, 10 000
-
Zagreb, Croatia, 10090
-
-
-
-
-
Arcachon, France
-
Caen, France, 14000
-
Elancourt, France, 78990
-
Le Pecq, France, 78230
-
Rennes, France, 35000
-
Savigny sur Orge, France
-
Strasbourg, France, 67100
-
Toulouse, France, 31000
-
Toulouse, France, 31300
-
Toulouse, France
-
Verasailles, France, 78000
-
-
-
-
-
Balassagyarmat, Hungary, 2660
-
Budapest, Hungary, 1083
-
Budapest, Hungary, 1134
-
Budapest, Hungary, 1135
-
Cegled, Hungary, 2700
-
Nyiregyhaza, Hungary, 4412
-
-
-
-
-
Belchatow, Poland, 97-400
-
Bydgoszcz, Poland
-
Krakow, Poland, 31-530
-
Lodz, Poland, 90-130
-
Lublin, Poland, 20-109
-
Torun, Poland, 87-100
-
Tuszyn, Poland, 95-080
-
-
-
-
-
Bucuresti, Romania, 041902
-
Lasi, Romania, 700282
-
Oradea, Romania, 410154
-
-
-
-
-
Arkhangelsk, Russian Federation, 163001
-
Belchatow, Russian Federation, 91-400
-
Moscow, Russian Federation, 115522
-
Moscow, Russian Federation, 107076
-
Moscow, Russian Federation, 125367
-
St. Petersburg, Russian Federation, 190121
-
St. Petersburg, Russian Federation, 191180
-
St. Petersburg, Russian Federation, 192019
-
St. Petersburg, Russian Federation, 194044
-
St. Petersburg, Russian Federation, 197341
-
St. Petersburg, Russian Federation, 198020
-
Stavropol, Russian Federation, 355108
-
-
-
-
-
Beograd, Serbia, 11 000
-
Beograd, Serbia, 11000
-
Kragujevac, Serbia, 34 000
-
NIS, Serbia, 18000
-
NIS, Serbia
-
Novi Sad, Serbia, 21 000
-
-
-
-
-
Crimea, Ukraine, 95006
-
Dnepropetrovsk, Ukraine, 49005
-
Kiev, Ukraine, 02660
-
Kiev, Ukraine, 03049
-
Kiev, Ukraine, 04080
-
Lviv, Ukraine, 79021
-
Odessa, Ukraine, 65000
-
Vinnitsa, Ukraine, 21005
-
-
Pobeda District
-
Donetsk, Pobeda District, Ukraine, 83037
-
-
-
-
-
Coventry, United Kingdom
-
Fowey, United Kingdom, PL23 1DT
-
Glasgow, United Kingdom, G20 OXA
-
Harrow, United Kingdom, HA13UJ
-
Haywards Heath, United Kingdom, RH16 4BE
-
Plymouth, United Kingdom, PL6 7TH
-
Warks, United Kingdom, CV32 4RA
-
-
Bath
-
Avon, Bath, United Kingdom, BA 1 2SR
-
-
Scotland
-
Glasgow, Scotland, United Kingdom, G51 4TF
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects must be male or female between the ages of 18 and 64, inclusive, at the time of signing consent.
- Subjects must have a primary diagnosis of Major Depressive Disorder (MDD) by DSM-IV criteria (296.XX) as determined by the Mini International Neuropsychiatric Interview (M.I.N.I.).
- MDD must be the condition that was chiefly responsible for motivating the subject to seek treatment.
- Subjects must have a 17-item Hamilton Depression Scale (HAM-D-17) total score of > 22 at the screening visit.
Exclusion Criteria:
- Subjects who have a HAM-D-17 total score < 18 at Visit 2 will be discontinued from the study.
- All subjects who do not meet DSM-IV criteria (307.42) for Insomnia related to a Major Depressive Disorder.
- Subjects with less than a total sleep time < 6.5 hours at least three times per week over the past month.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Placebo
|
Placebo
Venlafaxine 75 mcg Weeks 1, 2, 29, and 30 Venlafaxine 150 mcg Weeks 3 through 28
Other Names:
|
|
Experimental: Eszopiclone
|
Eszopiclone 3 mg
Other Names:
Venlafaxine 75 mcg Weeks 1, 2, 29, and 30 Venlafaxine 150 mcg Weeks 3 through 28
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The primary endpoint is the change from baseline in HAM-D-17 total score at Week 8.
Time Frame: Week 8
|
Week 8
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The key secondary endpoint is the change from baseline in the mean subjective Total Sleep Time (TST) during Week 1.
Time Frame: Week 1
|
Week 1
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Medical Director, CNS, Sunovion
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Pathologic Processes
- Nervous System Diseases
- Mood Disorders
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Depression
- Depressive Disorder
- Disease
- Sleep Initiation and Maintenance Disorders
- Depressive Disorder, Major
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Antidepressive Agents
- Hypnotics and Sedatives
- Antidepressive Agents, Second-Generation
- Serotonin and Noradrenaline Reuptake Inhibitors
- Venlafaxine Hydrochloride
- Eszopiclone
Other Study ID Numbers
Other Study ID Numbers
- 190-062
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.